Skip to Content
Merck
All Photos(1)

Documents

SML2159

Sigma-Aldrich

Minodronic acid monohydrate

≥98% (HPLC)

Synonym(s):

[1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene]bisphosphonic acid monohydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H12N2O7P2 · H2O
CAS Number:
155648-60-5
Molecular Weight:
340.16
MDL number:
MFCD20037380
UNSPSC Code:
12352106
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

0.1 M NaOH: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2N1C=CC=C2.O

InChI

1S/C9H12N2O7P2.H2O/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8;/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18);1H2

InChI key

GPAPAOGRNKUFGH-UHFFFAOYSA-N

Biochem/physiol Actions

Minodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Motoaki Yasukawa et al.
Anticancer research, 36(11), 5883-5886 (2016-10-30)
Non-small cell lung carcinoma (NSCLC) is one of the leading causes of cancer-related death worldwide. Recent studies showed that nitrogen-containing bisphosphonates (N-BPs) directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cell. In order
Shinichi Nakatoh
Journal of bone and mineral metabolism, 36(2), 221-228 (2017-03-16)
This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 µg/day) administration.
Tsuyoshi Ohishi et al.
Endocrine research, 42(3), 232-240 (2017-03-21)
Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service